drug · antibody
patient view →GP-2
Phase 3updated 2mo agoby $GLSI Greenwich LifeSciences, Inc.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 146 investigational indications.
targets
Vascular endothelial growth factor A, long form
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that